Stay updated on De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial

Sign up to get notified when there's something new on the De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a significant update in the clinical trial evaluating a new combination of treatments for Oropharyngeal Squamous Cell cancers (OPSCC) compared to the current standard of care, with a focus on demonstrating equivalent oncologic outcomes with fewer adverse effects and improved quality of life.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:06.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    41%
    Check dated 2024-05-22T21:17:31.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:31:40.000Z thumbnail image

Stay in the know with updates to De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial page.